Hematopoietic Stem Cell Transplantation
Study offers insights into COVID-19 vaccination, infection among HSCT recipients
NEW ORLEANS — Most hematopoietic stem cell transplant recipients received at least one dose of COVID-19 vaccine, according to single-institution study results presented at ASH Annual Meeting and Exposition.
ASH recap: New regimens for blood cancers; gene therapy equitable for sickle cell disease
This year’s ASH Annual Meeting and Exposition spotlighted practice-changing research in malignant and benign hematology.
Stem cell transplantation underutilized for acute myeloid leukemia
NEW ORLEANS — Utilization of hematopoietic stem cell transplantation for acute myeloid leukemia has increased over time but remains far below optimal levels, according to study results presented at ASH Annual Meeting and Exposition.
Restrictive diet an 'unnecessary burden' for patients undergoing HSCT
NEW ORLEANS — Adults undergoing stem cell transplant who received a nonrestrictive diet had similar rates of infection, feeding outcomes and acute graft-versus-host disease as those on a low-microbial protective diet, according to a study.
Data support less aggressive approach before transplant in relapsed/refractory AML
NEW ORLEANS — Skipping intensive remission-induction chemotherapy prior to allogeneic hematopoietic stem cell transplant did not impact survival outcomes among patients with relapsed/refractory acute myeloid leukemia, according to a study.
Non-European HSCT recipients undergo more complex procedures with fewer resources
Hematopoietic stem cell transplant recipients of non-European ancestry had a significantly higher likelihood of receiving allogeneic grafts from HLA-mismatched donors than individuals of European ancestry, study results showed.
Cytomegalovirus Management Curbside Consults: When Should Prophylaxis or Preemptive Therapy Start for At-Risk Patients, and How Long Should It Continue?
This activity is supported by an educational grant from Merck & Co., Inc.
Cytomegalovirus Management Curbside Consults: Management of At-Risk Patients With Reactivated CMV
This activity is supported by an educational grant from Merck & Co., Inc.
Eprenetapopt regimen beneficial after HSCT for TP53-mutant AML, myelodysplastic syndrome
Maintenance therapy with eprenetapopt plus azacitidine after hematopoietic stem cell transplantation led to improved survival outcomes among patients with TP53-mutant acute myeloid leukemia or myelodysplastic syndrome, study results showed.
Fludarabine shortage requires flexibility, alternative approaches for CAR-T and HSCT
For the second time in the last 2 years, a drug related to the administration of cellular therapy — fludarabine — has been placed on the FDA’s drug shortage list.